Eriko Taniai Selected Research

Fenbendazole

8/2010	Disruption of Smad-dependent signaling for growth of GST-P-positive lesions from the early stage in a rat two-stage hepatocarcinogenesis model.
4/2010	Induction of GST-P-positive proliferative lesions facilitating lipid peroxidation with possible involvement of transferrin receptor up-regulation and ceruloplasmin down-regulation from the early stage of liver tumor promotion in rats.
5/2009	Crosstalk between PTEN/Akt2 and TGFbeta signaling involving EGF receptor down-regulation during the tumor promotion process from the early stage in a rat two-stage hepatocarcinogenesis model.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eriko Taniai Research Topics

Disease

14	Neoplasms (Cancer) 01/2014 - 12/2008
3	Carcinogenesis 01/2014 - 01/2012
2	Body Weight (Weight, Body) 01/2012 - 08/2011
2	Neuroendocrine Carcinoma 07/2011 - 09/2010
1	Chromosomal Instability (Chromosome Stability) 06/2013
1	IGA Glomerulonephritis (IGA Nephropathy) 06/2012
1	Inflammation (Inflammations) 01/2012
1	Neuroblastoma 03/2009

Drug/Important Bio-Agent (IBA)

4	Glutathione Transferase (Glutathione S-Transferase)IBA 08/2010 - 05/2009
3	CarcinogensIBA 06/2013 - 01/2012
3	EnzymesIBA 01/2012 - 05/2010
3	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 01/2012 - 01/2011
3	indole-3-carbinolIBA 09/2011 - 01/2011
3	AntioxidantsIBA 09/2011 - 05/2010
3	Piperonyl Butoxide FDA Link 08/2010 - 05/2009
3	FenbendazoleIBA 08/2010 - 05/2009
3	Thioacetamide (Thioacetamid)IBA 08/2010 - 05/2009
2	Proteins (Proteins, Gene)FDA Link 01/2014 - 01/2012
2	Omeprazole (Prilosec)FDA LinkGeneric 01/2012 - 01/2012
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2012 - 01/2011
2	Chromogranin AIBA 07/2011 - 09/2010
2	SynaptophysinIBA 09/2010 - 03/2009
2	Phenobarbital (Luminal)FDA Link 08/2010 - 04/2010
2	MetalsIBA 05/2010 - 04/2010
1	SMTP 7IBA 06/2012
1	nivalenolIBA 06/2012
1	Immunoglobulin A (IgA)IBA 06/2012
1	Drinking WaterIBA 01/2012
1	trans-crotonin (CTN)IBA 01/2012
1	Pharmaceutical PreparationsIBA 01/2012
1	thiobarbituric acidIBA 01/2012
1	Thiobarbituric Acid Reactive SubstancesIBA 01/2012
1	Messenger RNA (mRNA)IBA 09/2011
1	Flutamide (Eulexin)FDA LinkGeneric 09/2011
1	Aminobutyrates (Aminobutyric Acid)IBA 08/2011
1	Glutamate Decarboxylase (Decarboxylase, Glutamate)IBA 08/2011
1	Acetylcysteine (Siran)FDA LinkGeneric 01/2011
1	Keratins (Keratin)IBA 09/2010
1	SilverIBA 09/2010
1	Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))IBA 09/2010
1	Transforming Growth Factors (Transforming Growth Factor)IBA 08/2010
1	Heme Oxygenase-1IBA 05/2010
1	CytokinesIBA 05/2010
1	IronIBA 05/2010
1	CopperIBA 05/2010
1	Ceruloplasmin (Ferroxidase)IBA 04/2010
1	Transferrin Receptors (Transferrin Receptor)IBA 04/2010
1	MetallothioneinIBA 04/2010
1	ErbB Receptors (EGF Receptor)IBA 05/2009
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 05/2009
1	Transforming Growth Factor beta (TGF-beta)IBA 05/2009
1	PTEN Phosphohydrolase (PTEN Phosphatase)IBA 05/2009
1	TensinsIBA 05/2009
1	tyrosine receptor (receptor, tyrosine)IBA 05/2009
1	Phosphotransferases (Kinase)IBA 05/2009
1	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 03/2009
1	Biological ProductsIBA 03/2009
1	NestinIBA 03/2009
1	Fenofibrate (CiL)FDA LinkGeneric 12/2008

Therapy/Procedure

1	Intraperitoneal Injections 08/2011
1	Aftercare (After-Treatment) 04/2010